德展健康，创5年来最大亏损

Group 1 - The company, Dezhan Health, forecasts a significant loss of between 175 million to 350 million yuan for 2025, marking the largest loss in five years, compared to a loss of 20.41 million yuan in 2024 [1] - From 2021 to 2025, the company has reported losses in four out of five years, with a profit of 83 million yuan only in 2023 [1] - The company attributes the expected losses to ongoing investments in nurturing business and R&D, the impact of centralized procurement policies on revenue, and impairment provisions for long-term equity investments and goodwill [1] Group 2 - Dezhan Health, originally Tianshan Textile, is the only listed pharmaceutical and health company within the Xinjiang state-owned asset system [1] - On September 16, 2025, the company underwent a management change, appointing Wei Zheming as chairman and Liu Wei as co-chairman and general manager, along with several other executive appointments [1] - On December 13, 2025, Wang Shubin, who had been in the role for less than three months, resigned from his position as vice president due to personal reasons [2] - The company is involved in a lawsuit related to a contract dispute between its former controlling shareholder and another company, which has been filed in the Beijing Third Intermediate People's Court [2] - Dezhan Health is among over 12 pharmaceutical companies implicated in a bribery case involving a hospital's pharmacy director [2][3]